中国药物评价2018，Vol.35Issue(6)：463-474,12.
ERCC1基因多态性与非小细胞肺癌患者铂类化疗疗效相关性的Meta分析
A Meta-analysis of the Association Between ERCC1 Gene Polymorphisms and the Efficacy of Platinum-based Chemotherapy in Non-small Cell Lung Cancer Patients
摘要
Abstract
Objective:The relationship between Excision Repair Cross-Complementation Group 1 (ERCC1) gene polymorphisms and the efficacy of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients was systematically evaluated to determine whether ERCC1 gene polymorphisms could be used as a predictor of the efficacy of platinum-based chemotherapy in NSCLC patients.And the organic combination of evidence based medicine and precision drug treatment regimen, to provide a basis for the adjustment of the clinical dose of platinum drugs, in order to improve the efficiency of chemotherapy regimens.Methods:All studies involving the association of the ERCC1 gene polymorphisms with the efficacy of platinum-based chemotherapy in NSCLC patients were systematically searched, including English database:Pub Med, Embase, Cochrane Library;Chinese database:CBM, CNKI, WANFANG, VIP.Establish strict inclusion and exclusion criteria for the literatures, screen high-quality cohort studies for Meta-analysis.The outcome of the analysis is objective response rate (ORR). The association between single nucleotide polymorphisms (SNPs) and ORR was assessed by calculating the odds ratio (OR) and the 95％confidence interval (CI). All analyzes were performed using the Review Manager version 5.3.Results:A total of 18 related studies, 2380 NSCLC patients were included in this Meta-analysis.According to the results of this study, there was no statistical evidence of a association between the ERCC1 gene polymorphisms and the efficacy of platinum-based chemotherapy in NSCLC patients.ERCC1 C118T:dominant model (CT+TT vs CC:OR=0.95, 95％CI=0.68-1.34, P=0.78), and the codominant model (CT vs CC:OR=0.77, 95％CI=0.57-1.03, P=0.08;TT vs CC:OR=1.00, 95％CI=0.49-2.05, P=0.99). ERCC1C8092A:dominant model (CA+AA vs CC:OR=1.00, 95％CI=0.79-1.27, P=0.98), and the codominant model (CA vs CC:OR=0.85, 95％CI=0.56-1.29, P=0.44;AA vs CC:OR=0.54, 95％CI=0.09-3.36, P=0.51). Conclusion:This Meta-analysis found no association between ERCC1 gene polymorphisms and the efficacy of platinum-based chemotherapy in NSCLC patients.The research evidence is not sufficient to prove that ERCC1 gene polymorphisms can predict the efficacy of platinum-based chemotherapy in NSCLC patients.However, given the limitations and heterogeneity of this Meta-analysis, the conclusions need to be interpreted cautiously.The future requires larger prospective studies and more rigorous research designs to test these conclusions.关键词
切除修复交叉互补基因1/基因多态性/非小细胞肺癌/铂类/Meta分析Key words
Excision Repair Cross-Complementation Group 1 (ERCC1) /Gene polymorphisms/Non-small cell lung cancer/Platinum-based/Meta-analysis分类
医药卫生引用本文复制引用
张凌雄,张阳,宋沧桑,杨琨琨..ERCC1基因多态性与非小细胞肺癌患者铂类化疗疗效相关性的Meta分析[J].中国药物评价,2018,35(6):463-474,12.基金项目
云南省卫生科技计划项目(No.2017NS088) （No.2017NS088）
